Saturday night, the U.S. Food and Drug Administration approved a Covid-19 treatment developed by Regeneron Pharmaceuticals, using monoclonal antibodies to mimic the body’s immune system. Its action is similar to a treatment by Eli Lilly and Company, approved 9 November. The Regeneron product was used to treat President Trump during his hospitalization – which he touted as a “cure,” though it is not. Regeneron hopes to have 300,000 doses available by the end of December; like Lilly’s drug, it’s expected to cost about US$ 1500. (

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.